Anifrolumab in the treatment of recurrent systemic lupus erythematosus: the first post-trial case report

Przemysław Borowy; Alicja Kamińska; Patrycja Major; Jakub Smyk; Katarzyna Gołojuch; Bogdan Batko

doi:10.5114/ceji.2025.148001

eISSN: 1644-4124
ISSN: 1426-3912

Central European Journal of Immunology

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Send email

Copy url:

abstract:

Case report

Anifrolumab in the treatment of recurrent systemic lupus erythematosus: the first post-trial case report

Przemysław Borowy

^{1, 2}

,

Alicja Kamińska

³

,

Patrycja Major

⁴

,

Jakub Smyk

⁵

,

Katarzyna Gołojuch

⁵

,

Bogdan Batko

^{1, 2}

Department of Rheumatology and Immunology, J. Dietl Hospital, Krakow, Poland
Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland
Stefan Żeromski Specialist Hospital, Kraków, Poland
5th Military Clinical Hospital in Kraków, Kraków, Poland
Ludwik Rydygier Memorial Hospital, Kraków, Poland

Cent Eur J Immunol 2025; 50 (1)

DOI: https://doi.org/10.5114/ceji.2025.148001

Online publish date: 2025/03/04

View full text Get citation

PlumX metrics:

Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease whose treatment is still a challenge. The latest registration of anifrolumab for the treatment of moderate-to-severe SLE raises hopes because of its novel anti-interferon mechanism of action. Anifrolumab, a human monoclonal antibody, selectively binds the interferon α (INF-α) receptor, inhibiting systemic inflammation moderated by interferon pathways. The article presents the first case of an 18-year-old man with severe, relapsing and repeatedly hospitalized SLE, successfully treated with anifrolumab.

During a subsequent exacerbation with multi-organ involvement, which could not be controlled despite pulses and high doses of glucocorticoids (GCSs), treatment with anifrolumab was initiated. Clinical improvement was achieved 4 weeks after the first dose. The patient’s dose of systemic GCSs was gradually reduced until complete withdrawal. No serious side effects were observed throughout the follow-up period, and the criteria for complete remission were achieved by the patient at month 3 of therapy. After 12 months, therapy was discontinued due to a payer decision. Nevertheless, the patient remains in follow-up 14 months after the completion of therapy on stable treatment with hydroxychloroquine and azathioprine. He is still not taking prednisone. This is the first case in Poland to show the fate of a “real life patient” after completion of anifrolumab therapy, an effective clinical remission of many months without the use of oral GCSs.

keywords:

Anifrolumab in the treatment of recurrent systemic lupus erythematosus: the first post-trial case report

Przemysław Borowy 1, 2 , Alicja Kamińska 3 , Patrycja Major 4 , Jakub Smyk 5 , Katarzyna Gołojuch 5 , Bogdan Batko 1, 2

SLE, case report, GCS, interferon, anifrolumab

Przemysław Borowy

^{1, 2}

,

Alicja Kamińska

³

,

Patrycja Major

⁴

,

Jakub Smyk

⁵

,

Katarzyna Gołojuch

⁵

,

Bogdan Batko

^{1, 2}